Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Transition to product patent - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 6, 2004

    Pharma: Transition to product patent

    January 1, 2005 is the day when Indian pharmaceutical sector will take its first step towards the fundamental shift from an unregulated market to a regulated market (though not as stringent as US or some European countries). Till date, government price controls and patent laws have determined the structure of the domestic pharmaceutical market. Although, the industry was in tight controls it still managed to grow at a rapid pace.

    Since 1970, when the Patent Act came into force, the industry has grown by almost 14% CAGR till 2003. This growth was led by the global orientation of Indian pharmaceutical industry. The pharmaceutical exports of the country has grown at a rapid pace of almost 30% in last 15 years, thanks to increasing the cost efficiencies of Indian manufacturers. In the last few years, the domestic pharma market too has shown considerable growth (over 12.5% CAGR since 1970). The growth would have been much higher, had it not been for the fragmented nature of the industry (over 20,000 pharma companies). This has led to competitive and thus pricing pressure.

    From 2005, the Indian pharmaceutical industry is set to move towards product patent regime (earlier it was process patent regime). This essentially means that a product for which patent has been granted or for which patent application has been submitted after January 1, 1995, cannot be reverse engineered and launched in the market by the generic companies. In light of this, the next decade is likely to see a fundamental shift in the industry structure.

    Post 2005 we do not expect any drastic change in the industry growth rate of 6%-8%, which has been witnessed in the last 2-3 years. Our interaction with pharma companies (both MNC and domestic) suggests that patented products are likely to contribute significantly only after 2010 and may contribute about 8%-10% of revenues after 2010.

    But the impact on domestic companies will be seen beyond 2007 or so, as new product introduction by these companies might slow down owing to the new product patent law. However, there are domestic companies, which have option of partnering with MNC companies that do not have a presence in India. Companies like Nicholas Piramal and Cadila Healthcare have already begun this process by strengthening their field force. Infact, Nicholas Piramal has started this process by entering into agreements with Ethypharma and Genzyme Corporation.

    We do not foresee slackening of price competition in near future, but new-patented products with significant therapeutic advantage over the already existing products may see higher pricing as patients and doctors will like to move towards those products for better treatment. There might be price differential of more than 10 times in some cases. However, how much market share these new products will be able to get, depends on the purchasing power and the demographic profile of India.

    However, it must be noted that the increasing activity in the economy and rapidly growing services sector has improved the purchasing power of Indian consumers. One thing to note here is that most of the new therapies are likely to come from the lifestyle segment, and people suffering from these diseases are more likely to pay higher for better therapeutic affect. Also, going forward we might see consolidation in the Indian pharmaceutical industry. Smaller players even in the organised sector might not be able to cope up with the changing environment.

    However, one positive aspect that emerges out of this transition is that Indian companies are now focusing on R&D activities and are investing in developing NCE and NDDS products. This will lead to large domestic companies surviving the heat of competition by virtue of innovation. Already large Indian companies such as Ranbaxy, Dr Reddy's and Wockhardt have made significant R&D inroads, while smaller companies such as Glenmark Pharma and Orchid Chemicals are moving towards it. Going forward, we may see higher R&D expenditure to the tune of 7%-10% of revenues.

    In the new regime, MNC pharma companies are likely to benefit the most. However, we do not expect MNC pharmaceutical companies to register immediate gains post 2005, but these companies will have advantage of their strong parent drug pipeline in the long run. Companies, which have strong presence in the domestic market, will have an added advantage on marketing front. According to us, companies like Glaxo, Pfizer and Aventis are likely to benefit the most in this scenario.

    As an investor, one should look at both Indian as well as MNC pharma companies as an investment avenue. While MNC pharma companies are sure to benefit in the long run in this new patent regime, which pharma company will benefit the most is the question. It must be noted that MNC companies, which have strong parent back up and big marketing presence are likely to benefit the most. While, bigger Indian companies are likely to gain from their international operations, they will also benefit from Indian operations if they continue focusing on R&D activities.



    Equitymaster requests your view! Post a comment on "Pharma: Transition to product patent". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)